Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

(2022) Lisa Derosa et al.   NATURE MEDICINE

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

(2022) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer

(2021) Monika Pradhan et al.   Translational Lung Cancer Research

Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

(2021) Bruno V. Sinn et al.   CLINICAL CANCER RESEARCH

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

(2021) E. A. Rozeman et al.   NATURE MEDICINE

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

(2021) Alexander M. Menzies et al.   NATURE MEDICINE

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

(2021) Tina Cascone et al.   NATURE MEDICINE

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

(2021) Sandra J. Casak et al.   CLINICAL CANCER RESEARCH

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

(2021) J. Lee et al.   Journal of Thoracic Oncology

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

(2021) Nasser K Altorki et al.   LANCET ONCOLOGY

Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment

(2021) Annikka Weissferdt et al.   LUNG CANCER

Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer

(2021) Jamie E. Chaft et al.   Nature Reviews Clinical Oncology

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

(2021) Ronan J. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Next Decade of Immune Checkpoint Therapy

(2021) Padmanee Sharma et al.   Cancer Discovery

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

(2021) D. Miles et al.   ANNALS OF ONCOLOGY

LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

(2021) J. Cortés et al.   ANNALS OF ONCOLOGY

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma

(2021) R.V. Rawson et al.   ANNALS OF ONCOLOGY

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

(2021) Leigh Marcus et al.   CLINICAL CANCER RESEARCH

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

(2021) Sacha I. Rothschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

(2021) Enriqueta Felip et al.   LANCET

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

(2021) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

(2021) Tina Cascone et al.   Nature Communications

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

(2021) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

(2021) Joris L. Vos et al.   Nature Communications

Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy

(2020) Annikka Weissferdt et al.   Clinical Lung Cancer

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY

(2020) William D. Travis et al.   Journal of Thoracic Oncology

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

(2020) T. Karn et al.   ANNALS OF ONCOLOGY

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer.

(2020) Tina Cascone et al.   CLINICAL CANCER RESEARCH

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

(2020) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

(2020) Catherine A Shu et al.   LANCET ONCOLOGY

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

(2020) Myriam Chalabi et al.   NATURE MEDICINE

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

(2020) Elizabeth A Mittendorf et al.   LANCET

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

(2020) Aurélien Marabelle et al.   LANCET ONCOLOGY

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

(2020) Mariano Provencio et al.   LANCET ONCOLOGY

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

(2020) Nick van Dijk et al.   NATURE MEDICINE

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma

(2020) Jonathan D. Schoenfeld et al.   JAMA Oncology

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

(2020) Javier Cortes et al.   LANCET

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

(2019) Deborah B Doroshow et al.   CLINICAL CANCER RESEARCH

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study

(2019) S Loibl et al.   ANNALS OF ONCOLOGY

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

(2019) Rodabe N Amaria et al.   LANCET ONCOLOGY

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

(2019) Elisa A Rozeman et al.   LANCET ONCOLOGY

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

(2019) Julie E Stein et al.   CLINICAL CANCER RESEARCH

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

(2019) Jason J Luke et al.   Future Oncology

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

(2018) M T Tetzlaff et al.   ANNALS OF ONCOLOGY

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

(2018) T R Cottrell et al.   ANNALS OF ONCOLOGY

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer

(2018) Tina Cascone et al.   ANNALS OF THORACIC SURGERY

The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy

(2018) Vancheswaran Gopalakrishnan et al.   CANCER CELL

The gut microbiota influences anticancer immunosurveillance and general health

(2018) Bertrand Routy et al.   Nature Reviews Clinical Oncology

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Adjuvant Pembrolizumab in Resected Stage III Melanoma

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

(2018) Andrea Necchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

(2018) Rodabe N. Amaria et al.   NATURE MEDICINE

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

(2018) Christian U. Blank et al.   NATURE MEDICINE

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Diminished but not dead: chemotherapy for the treatment of NSCLC

(2016) Roy S Herbst et al.   LANCET ONCOLOGY

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer

(2014) L. Amiri-Kordestani et al.   CLINICAL CANCER RESEARCH

Defining success in neoadjuvant breast cancer trials

(2014) Lisa A Carey et al.   LANCET

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

(2014)   LANCET

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

(2014) Matthew D Hellmann et al.   LANCET ONCOLOGY

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

(2012) Apar Pataer et al.   Journal of Thoracic Oncology

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY